media – Page 645 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Merck Discontinues MK-3682B and MK-3682C Development Programs

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced its strategic decision to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection.
- Source: Mrknewsroom
- 600
- September 30, 2017
chronic hepatitis C virus (HCV) infection Market Views Merck
FDA approves new treatment for certain advanced or metastatic breast cancers

The U.S. Food and Drug Administration(FDA) approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).
- Source: fda.gov
- 906
- September 30, 2017
breast cancer FDA New Approvals therapy
Lab Asia

LabAsia Kuala Lumpur is the LARGEST Lab Exhibition in Southeast Asia (SEA). LabAsia started its first step into the Indonesia market by launching LabIndonesia, which turn out to be a success. LabAsia and LabIndonesia are held biannually alternately.
- Source: medical-events.info
- 659
- September 30, 2017
Exhibitions & Activities Lab Asia
THE PREMIER MIDWEST EVENT FOR SENSORS AND SENSOR SYSTEMS

As the growth of the sensors market continues to rapidly expand, Sensors Midwest will bring together thousands of engineers in the Midwest marketplace looking for access to the latest sensor advancements and will provide an opportunity to connect with the area's greatest technology leaders and suppliers. Sensors Midwest is your one-stop show for exploring the latest technologies in the industry, education, and networking. Everything you and your business need to be successful will be found at #SensorsMW17!
- Source: sensorsmidwest
- 478
- September 29, 2017
Exhibitions & Activities sensor SensorsMW17
FDA rejects Intarcia’s hotly promoted diabetes drug/device, citing manufacturing issues

Boston-based Intarcia Therapeutics became the latest casualty of the FDA’s manufacturing standards. The agency has rejected Intarcia’s implanted diabetes drug/device, which company execs have long insisted is on a straight path to blockbuster sales.
- Source: Endpts
- 432
- September 29, 2017
Company Insight diabetes implanted
Two Scientists Nab Another $20 Million for Their CRISPR Biotech Eligo Bioscience

Eligo Bioscience, the French microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured a $20 million Series A round of financing from Khosla Ventures and Seventure Partners, including a $2 million award from the Worldwide Innovation Challenge. This comes just months after Eligo was selected as one of the 30 Most Innovative Companies in 2017 by the World Economic Forum. This funding will enable Eligo to strengthen its biotherapeutic platform, begin clinical trials for its lead indication and extensively grow its international team of scientists, engineers, and executives.
- Source: Biospace
- 535
- September 29, 2017
Market Views microbiome Series
Novo Nordisk’s new-generation basal insulin Tresiba® approved in China

Novo Nordisk announced that the China Food and Drug Administration (CFDA) has approved Tresiba® (insulin degludec) for the treatment of diabetes in China. Tresiba® is a new-generation, once-daily basal insulin with an ultra-long duration of action which allows for flexibility in day-to-day dosing.
- Source: Novonordisk
- 552
- September 29, 2017
CFDA diabetes New Approvals Tresiba
Innovative Business Development Strategies for the Modern Medical Trade

International business development has been reliant on a couple of trusty old work horses for some time now. Google, development letters and site visits have lead the charge and they are very effective when used correctly. They can however, be costly and time consuming and with the ever-changing world that we live in. New ways of development are constantly making an appearance and if you want your business to prosper, adaptation is key.
- Source: Ddu
- 572
- September 28, 2017
business development Ddu College
Boehringer’s new risk-prediction model will tap patients who could be good Jardiance candidates

Boehringer Ingelheim has reason to believe its diabetes medication Jardiance can help fend off cardiovascular death, kidney failure and hospitalization for heart failure. And now, it’s developing a model to help predict which patients are best suited for treatment with the therapy.
- Source: company insights
- 569
- September 28, 2017
cardiovascular Company Insight diabetes kidney
Siemens gets CE-Mark for new diagnostic solution

Siemens Healthineers has received CE-Mark for its new Atellica Solution with immunoassay and chemistry analysers, which will allow commercial launch in Europe.
- Source: medicaldevice-network
- 554
- September 28, 2017
CE IVD New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.